Overexpression of human apolipoprotein A-I in transgenic rats and the hyperlipoproteinemia associated with experimental nephrosis

Hyperlipoproteinemia contributes both to kidney disease progression and the development of atherosclerosis. Elevated high density lipoprotein cholesterol and apolipoprotein A-I (apoA-I) serum levels are independent factors protective against the atherosclerotic process. We examined the effects in a...

Full description

Bibliographic Details
Main Authors: B F Burkey, D France, H Wang, X Ma, B Brand, C Abuhani, M R Diffenderfer, J B Marsh, J R Paterniti, Jr, E A Fisher
Format: Article
Language:English
Published: Elsevier 1995-07-01
Series:Journal of Lipid Research
Online Access:http://www.sciencedirect.com/science/article/pii/S0022227520397339
id doaj-aaa82e1cec014fadb9102ce077fdd3b8
record_format Article
spelling doaj-aaa82e1cec014fadb9102ce077fdd3b82021-04-26T05:50:02ZengElsevierJournal of Lipid Research0022-22751995-07-0136714631473Overexpression of human apolipoprotein A-I in transgenic rats and the hyperlipoproteinemia associated with experimental nephrosisB F Burkey0D France1H Wang2X Ma3B Brand4C Abuhani5M R Diffenderfer6J B Marsh7J R Paterniti, Jr8E A Fisher9Department of Metabolic Diseases, Sandoz Research Institute, Sandoz Pharmaceuticals Corporation, East Hanover, NJ 07936, USA.Department of Metabolic Diseases, Sandoz Research Institute, Sandoz Pharmaceuticals Corporation, East Hanover, NJ 07936, USA.Department of Metabolic Diseases, Sandoz Research Institute, Sandoz Pharmaceuticals Corporation, East Hanover, NJ 07936, USA.Department of Metabolic Diseases, Sandoz Research Institute, Sandoz Pharmaceuticals Corporation, East Hanover, NJ 07936, USA.Department of Metabolic Diseases, Sandoz Research Institute, Sandoz Pharmaceuticals Corporation, East Hanover, NJ 07936, USA.Department of Metabolic Diseases, Sandoz Research Institute, Sandoz Pharmaceuticals Corporation, East Hanover, NJ 07936, USA.Department of Metabolic Diseases, Sandoz Research Institute, Sandoz Pharmaceuticals Corporation, East Hanover, NJ 07936, USA.Department of Metabolic Diseases, Sandoz Research Institute, Sandoz Pharmaceuticals Corporation, East Hanover, NJ 07936, USA.Department of Metabolic Diseases, Sandoz Research Institute, Sandoz Pharmaceuticals Corporation, East Hanover, NJ 07936, USA.Department of Metabolic Diseases, Sandoz Research Institute, Sandoz Pharmaceuticals Corporation, East Hanover, NJ 07936, USA.Hyperlipoproteinemia contributes both to kidney disease progression and the development of atherosclerosis. Elevated high density lipoprotein cholesterol and apolipoprotein A-I (apoA-I) serum levels are independent factors protective against the atherosclerotic process. We examined the effects in a transgenic rat model of human apoA-I expression on the hyperlipoproteinemia and edema after puromycin aminonucleoside-induced nephrosis in three groups of animals: low line (TgR[hAI]low, human plasma apoA-I = 16.0 mg/dl); high line (TgR[hAI]high, 284 mg/dl); and non-transgenic litter mates (TgR[hAI]non). Nephrosis increased total plasma apoA-I levels 2-fold in TgR[hAI]non rats (75 vs. 162 mg/dl) and 4-fold in the TgR[hAI]low (97 vs. 458 mg/dl) and TgR[hAI]high rats (356 vs. 1,346 mg/dl). In both transgenic lines, this increase was due mainly to elevations of serum human apoA-I. The hepatic steady-state levels of rat apoA-I mRNA increased 5- to 7-fold in all three groups, while human apoA-I mRNA levels increased 21- and 65-fold in the low and high expressing groups, respectively, indicating a different degree of responsiveness of the rat and human genes. While nephrotic TgR[hAI]non and TgR[hAI]low rats showed severe hyperlipoproteinemia and edema, much lower levels of edema and of serum triglycerides, phospholipids, and cholesterol were seen in the TgR[hAI]high group. Urinary excretion of apoA-I, phospholipids, and cholesterol was significantly increased in the TgR[hAI]high group, indicating this as one possible mechanism for the relatively lower serum levels of these lipids. We conclude that the human apoA-I gene is responsive to nephrosis and that human apoA-I-transgenic rats with this syndrome provide an animal model for the study of human high density lipoprotein and apoA-I metabolism.http://www.sciencedirect.com/science/article/pii/S0022227520397339
collection DOAJ
language English
format Article
sources DOAJ
author B F Burkey
D France
H Wang
X Ma
B Brand
C Abuhani
M R Diffenderfer
J B Marsh
J R Paterniti, Jr
E A Fisher
spellingShingle B F Burkey
D France
H Wang
X Ma
B Brand
C Abuhani
M R Diffenderfer
J B Marsh
J R Paterniti, Jr
E A Fisher
Overexpression of human apolipoprotein A-I in transgenic rats and the hyperlipoproteinemia associated with experimental nephrosis
Journal of Lipid Research
author_facet B F Burkey
D France
H Wang
X Ma
B Brand
C Abuhani
M R Diffenderfer
J B Marsh
J R Paterniti, Jr
E A Fisher
author_sort B F Burkey
title Overexpression of human apolipoprotein A-I in transgenic rats and the hyperlipoproteinemia associated with experimental nephrosis
title_short Overexpression of human apolipoprotein A-I in transgenic rats and the hyperlipoproteinemia associated with experimental nephrosis
title_full Overexpression of human apolipoprotein A-I in transgenic rats and the hyperlipoproteinemia associated with experimental nephrosis
title_fullStr Overexpression of human apolipoprotein A-I in transgenic rats and the hyperlipoproteinemia associated with experimental nephrosis
title_full_unstemmed Overexpression of human apolipoprotein A-I in transgenic rats and the hyperlipoproteinemia associated with experimental nephrosis
title_sort overexpression of human apolipoprotein a-i in transgenic rats and the hyperlipoproteinemia associated with experimental nephrosis
publisher Elsevier
series Journal of Lipid Research
issn 0022-2275
publishDate 1995-07-01
description Hyperlipoproteinemia contributes both to kidney disease progression and the development of atherosclerosis. Elevated high density lipoprotein cholesterol and apolipoprotein A-I (apoA-I) serum levels are independent factors protective against the atherosclerotic process. We examined the effects in a transgenic rat model of human apoA-I expression on the hyperlipoproteinemia and edema after puromycin aminonucleoside-induced nephrosis in three groups of animals: low line (TgR[hAI]low, human plasma apoA-I = 16.0 mg/dl); high line (TgR[hAI]high, 284 mg/dl); and non-transgenic litter mates (TgR[hAI]non). Nephrosis increased total plasma apoA-I levels 2-fold in TgR[hAI]non rats (75 vs. 162 mg/dl) and 4-fold in the TgR[hAI]low (97 vs. 458 mg/dl) and TgR[hAI]high rats (356 vs. 1,346 mg/dl). In both transgenic lines, this increase was due mainly to elevations of serum human apoA-I. The hepatic steady-state levels of rat apoA-I mRNA increased 5- to 7-fold in all three groups, while human apoA-I mRNA levels increased 21- and 65-fold in the low and high expressing groups, respectively, indicating a different degree of responsiveness of the rat and human genes. While nephrotic TgR[hAI]non and TgR[hAI]low rats showed severe hyperlipoproteinemia and edema, much lower levels of edema and of serum triglycerides, phospholipids, and cholesterol were seen in the TgR[hAI]high group. Urinary excretion of apoA-I, phospholipids, and cholesterol was significantly increased in the TgR[hAI]high group, indicating this as one possible mechanism for the relatively lower serum levels of these lipids. We conclude that the human apoA-I gene is responsive to nephrosis and that human apoA-I-transgenic rats with this syndrome provide an animal model for the study of human high density lipoprotein and apoA-I metabolism.
url http://www.sciencedirect.com/science/article/pii/S0022227520397339
work_keys_str_mv AT bfburkey overexpressionofhumanapolipoproteinaiintransgenicratsandthehyperlipoproteinemiaassociatedwithexperimentalnephrosis
AT dfrance overexpressionofhumanapolipoproteinaiintransgenicratsandthehyperlipoproteinemiaassociatedwithexperimentalnephrosis
AT hwang overexpressionofhumanapolipoproteinaiintransgenicratsandthehyperlipoproteinemiaassociatedwithexperimentalnephrosis
AT xma overexpressionofhumanapolipoproteinaiintransgenicratsandthehyperlipoproteinemiaassociatedwithexperimentalnephrosis
AT bbrand overexpressionofhumanapolipoproteinaiintransgenicratsandthehyperlipoproteinemiaassociatedwithexperimentalnephrosis
AT cabuhani overexpressionofhumanapolipoproteinaiintransgenicratsandthehyperlipoproteinemiaassociatedwithexperimentalnephrosis
AT mrdiffenderfer overexpressionofhumanapolipoproteinaiintransgenicratsandthehyperlipoproteinemiaassociatedwithexperimentalnephrosis
AT jbmarsh overexpressionofhumanapolipoproteinaiintransgenicratsandthehyperlipoproteinemiaassociatedwithexperimentalnephrosis
AT jrpaternitijr overexpressionofhumanapolipoproteinaiintransgenicratsandthehyperlipoproteinemiaassociatedwithexperimentalnephrosis
AT eafisher overexpressionofhumanapolipoproteinaiintransgenicratsandthehyperlipoproteinemiaassociatedwithexperimentalnephrosis
_version_ 1721508439285301248